JP Morgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Over

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Na

"Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- bre

WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD

Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday&

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.14) per share which beat the ana

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While

ADAR1 Capital Management LLC purchased a new position in shares of Prelude Therapeutics Incorporated

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, whic

US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings;

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Con

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.13) per share which beat the ana

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Pr

D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) w

Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmar

HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a

Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Bioasis Technologies (OTCMKTS:BIOAF - Get

In lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 s

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD

Title: First-in-Class potent and selective oral KAT6A degrader development candidate, PRT13722, driv

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Respon

WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD

Aptorum Group (NASDAQ: APM - Get Free Report) and Prelude Therapeutics (NASDAQ: PRLD - Get Free Repo

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD

Citizens analyst Reni Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperf

Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.20) per share which missed the a

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective

WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD)

Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - G

First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying pot

LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights li

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Progr